International Journal of Laboratory Hematology

Volume 44, Issue 3 pp. e95-e99

LETTER TO THE EDITOR

Effect of DOAC-Remove on coagulation screening assays in samples from patients receiving oral or parenteral anticoagulation

Zahra Al-Qawzai,

Zahra Al-Qawzai

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

Clinical Biochemistry Laboratory, The Royal London Hospital, Barts Health NHS Trust, London, UK

Search for more papers by this author

Chris Dale,

Chris Dale

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

Haemostasis Laboratory, The Royal London Hospital, Barts Health NHS Trust, London, UK

Search for more papers by this author

Minal Dave,

Minal Dave

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

Haemostasis Laboratory, The Royal London Hospital, Barts Health NHS Trust, London, UK

Search for more papers by this author

Nada Yartey,

Nada Yartey

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

Haemostasis Laboratory, The Royal London Hospital, Barts Health NHS Trust, London, UK

Search for more papers by this author

Sean Platton,

Corresponding Author

Sean Platton

[email protected]

orcid.org/0000-0002-5466-0448

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

The Royal London Hospital Haemophilia Centre, The Royal London Hospital, Barts Health NHS Trust, London, UK

Correspondence

Sean Platton, The Royal London Haemophilia Centre, Haematology Day Unit, The Royal London Hospital, Whitechapel E1 1BB, London.

Email: [email protected]

Search for more papers by this author

Zahra Al-Qawzai,

Zahra Al-Qawzai

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

Clinical Biochemistry Laboratory, The Royal London Hospital, Barts Health NHS Trust, London, UK

Search for more papers by this author

Chris Dale,

Chris Dale

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

Haemostasis Laboratory, The Royal London Hospital, Barts Health NHS Trust, London, UK

Search for more papers by this author

Minal Dave,

Minal Dave

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

Haemostasis Laboratory, The Royal London Hospital, Barts Health NHS Trust, London, UK

Search for more papers by this author

Nada Yartey,

Nada Yartey

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

Haemostasis Laboratory, The Royal London Hospital, Barts Health NHS Trust, London, UK

Search for more papers by this author

Sean Platton,

Corresponding Author

Sean Platton

[email protected]

orcid.org/0000-0002-5466-0448

NHS East and South East London Pathology Partnership, The Royal London Hospital, Barts Health NHS Trust, London, UK

The Royal London Hospital Haemophilia Centre, The Royal London Hospital, Barts Health NHS Trust, London, UK

Correspondence

Sean Platton, The Royal London Haemophilia Centre, Haematology Day Unit, The Royal London Hospital, Whitechapel E1 1BB, London.

Email: [email protected]

Search for more papers by this author

First published: 28 October 2021

https://doi.org/10.1111/ijlh.13743

Citations: 3

FUNDING INFORMATION

The DOAC-Remove for this study was donated by Quadratech Diagnostics (Epsom, UK). No other funding sources were used.

Share a link

Email
Wechat
Bluesky

CONFLICT OF INTEREST

Z Al-Qawzai, C Dale, N Yartey, M Dave and S Platton all declare no conflicts of interest.

Open Research

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

1Favaloro E, Pasalic L, Lippi G. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing. Pathology. 2017; 49: 639-643.
10.1016/j.pathol.2017.04.011
CAS PubMed Web of Science® Google Scholar
2Adcock DM, Gosselin R. Direct oral anticoagulants (DOACs) in the laboratory: 2015 review. Thromb Res. 2015; 136: 7-12.
10.1016/j.thromres.2015.05.001
CAS PubMed Web of Science® Google Scholar
3Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2018; 118: 437-450.
10.1055/s-0038-1627480
PubMed Web of Science® Google Scholar
4Exner T, Rigano J, Favaloro EJ. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. Int J Lab Hematol. 2020; 42(s1): 41-48.
10.1111/ijlh.13196
PubMed Web of Science® Google Scholar
5Cox-Morton S, MacDonald S, Thomas W. A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove. Br J Haematol. 2019; 187(3): 377-385.
10.1111/bjh.16091
CAS PubMed Web of Science® Google Scholar
6Kopytek M, Ząbczyk M, Malinowski KP, Undas A, Natorska J. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients. Clin Chem Lab Med. 2020; 58(3): 430-437.
10.1515/cclm-2019-0650
CAS PubMed Web of Science® Google Scholar
7Jourdi G, Delrue M, Stepanian A, et al. Potential usefulness of activated charcoal (DOAC-Remove) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. Thromb Res. 2019; 184: 86-91.
10.1016/j.thromres.2019.11.001
CAS PubMed Web of Science® Google Scholar
8 Human Tissue Act. 2004. Available from http://www.legislation.gov.uk/ukpga/2004/30/contents. Accessed February 1, 2021.
Google Scholar
9Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012; 157: 47-58.
10.1111/j.1365-2141.2012.09037.x
CAS PubMed Web of Science® Google Scholar
10Kitchen S, McCraw A, Echenagucia M. Diagnosis of Hemophilia and Other Bleeding Disorders: A Laboratory Manual, 2nd edn: World Federation of Hemophilia; 2010.
Google Scholar
11Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016; 38(5): 505-513. doi:10.1111/ijlh.12528.
10.1111/ijlh.12528
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume44, Issue3

June 2022

Pages e95-e99

Effect of DOAC-Remove on coagulation screening assays in samples from patients receiving oral or parenteral anticoagulation

CONFLICT OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Effect of DOAC-Remove on coagulation screening assays in samples from patients receiving oral or parenteral anticoagulation

CONFLICT OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature

References

Related

Information